These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. Lau SC; Abdel-Rahman O; Cheung WY Med Oncol; 2018 Aug; 35(9):123. PubMed ID: 30078166 [TBL] [Abstract][Full Text] [Related]
32. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study. Ballal S; Yadav MP; Damle NA; Sahoo RK; Bal C Clin Nucl Med; 2017 Nov; 42(11):e457-e466. PubMed ID: 28872545 [TBL] [Abstract][Full Text] [Related]
33. Investigation of receptor radionuclide therapy with Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927 [TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate. Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133 [TBL] [Abstract][Full Text] [Related]
35. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment. Hamiditabar M; Ali M; Roys J; Wolin EM; OʼDorisio TM; Ranganathan D; Tworowska I; Strosberg JR; Delpassand ES Clin Nucl Med; 2017 Jun; 42(6):436-443. PubMed ID: 28263217 [TBL] [Abstract][Full Text] [Related]
36. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410 [TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience. Satapathy S; Mittal BR; Sood A; Verma R; Panda N Nucl Med Commun; 2020 Jul; 41(7):629-635. PubMed ID: 32371670 [TBL] [Abstract][Full Text] [Related]
38. Salvage peptide receptor radionuclide therapy with [ van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of Abou Jokh Casas E; Pubul Núñez V; Anido-Herranz U; Del Carmen Mallón Araujo M; Del Carmen Pombo Pasín M; Garrido Pumar M; Cabezas Agrícola JM; Cameselle-Teijeiro JM; Hilal A; Ruibal Morell Á World J Gastroenterol; 2020 Apr; 26(13):1513-1524. PubMed ID: 32308351 [TBL] [Abstract][Full Text] [Related]
40. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]